Anonymous
Guest
Anonymous
Guest
Once again, Precedex and ACC will keep Hospira afloat for another year.
The patent extension and the pre-mix will provide enough profit to keep us moving forward until 2014.....Then What???? Can we survive on low margin generics for much longer? Can we reinvent our stained reputation? Will the India plant be our saviour?
Other product/company acquisitions? Biosimilars/Equivalents? They've been an elusive goal for the past 15 years.
My point....and final question.....when do we start looking for other employment?
The patent extension and the pre-mix will provide enough profit to keep us moving forward until 2014.....Then What???? Can we survive on low margin generics for much longer? Can we reinvent our stained reputation? Will the India plant be our saviour?
Other product/company acquisitions? Biosimilars/Equivalents? They've been an elusive goal for the past 15 years.
My point....and final question.....when do we start looking for other employment?